The first single agent ICI to be approved in HCC was the anti-PD-1 nivolumab, which demonstrated an objective response rate (ORR) of 15% in the phase I/II CheckMate-040 trial [4]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.